Literature DB >> 16146722

The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention.

Jose Russo1, Gabriela A Balogh, Jinqiang Chen, Sandra V Fernandez, Rachael Fernbaugh, Rebecca Heulings, Daniel A Mailo, Raquel Moral, Patricia A Russo, Fathima Sheriff, Johana E Vanegas, Richard Wang, Irma H Russo.   

Abstract

The breast attains its maximum development during pregnancy and lactation. After menopause the breast regresses in both nulliparous and parous women containing lobular structures that have been designated lobules type 1. Despite the similarity in the lobular composition of the breast at menopause, the fact that nulliparous women are at higher risk of developing breast cancer than parous women, indicates that Lobules type 1 in these two groups of women might be biologically different, or exhibit different susceptibility to carcinogenesis. Based on these observations it was postulated that the Lobule type 1 found in the breast of nulliparous women and of parous women with breast cancer never went through the process of differentiation, retaining a high concentration of epithelial cells that are targets for carcinogens and therefore susceptible to undergo neoplastic transformation, these cell are called Stem cells 1, whereas Lobules type 1 structures found in the breast of early parous postmenopausal women free of mammary pathology, on the other hand, are composed of an epithelial cell population that is refractory to transformation called Stem cells 2. It was further postulated that the degree of differentiation acquired through early pregnancy has changed the "genomic signature" that differentiates the Lobule type 1 from the early parous women from that of the nulliparous women by shifting the Stem cell 1 to a Stem cell 2 that is refractory to carcinogenesis, making this the postulated mechanism of protection conferred by early full term pregnancy. The identification of a putative breast stem cell (Stem cell 1) has reached in the last decade a significant impulse and several markers also reported for other tissues have been found in the mammary epithelial cells of both rodents and humans. Although still more work needs to be done in order to better understand the role of the Stem cell 2 and its interaction with the genes that confer it a specific signature, collectively, the data presently available provides evidence that pregnancy, through the process of cell differentiation, shifts the Stem cell 1 to Stem cell 2, cells that exhibit a specific genomic signature that could be responsible for the refractoriness of the mammary gland to carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16146722     DOI: 10.2741/1788

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  18 in total

1.  Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis.

Authors:  M A Kocdor; H Kocdor; J S Pereira; J E Vanegas; I H Russo; J Russo
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 2.  Pregnancy-induced changes in breast cancer risk.

Authors:  Irma H Russo; Jose Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-09       Impact factor: 2.673

3.  Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse.

Authors:  Dontscho Kerjaschki; Zsuzsanna Bago-Horvath; Margaretha Rudas; Veronika Sexl; Christine Schneckenleithner; Susanne Wolbank; Gregor Bartel; Sigurd Krieger; Romana Kalt; Brigitte Hantusch; Thomas Keller; Katalin Nagy-Bojarszky; Nicole Huttary; Ingrid Raab; Karin Lackner; Katharina Krautgasser; Helga Schachner; Klaus Kaserer; Sandra Rezar; Sybille Madlener; Caroline Vonach; Agnes Davidovits; Hitonari Nosaka; Monika Hämmerle; Katharina Viola; Helmut Dolznig; Martin Schreiber; Alexander Nader; Wolfgang Mikulits; Michael Gnant; Satoshi Hirakawa; Michael Detmar; Kari Alitalo; Sebastian Nijman; Felix Offner; Thorsten J Maier; Dieter Steinhilber; Georg Krupitza
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

4.  Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells.

Authors:  Thomas J Pogash; Karam El-Bayoumy; Shantu Amin; Krishne Gowda; Ricardo López de Cicco; Maria Barton; Yanrong Su; Irma H Russo; Julie A Himmelberger; Michael Slifker; Andrea Manni; Jose Russo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-11-21       Impact factor: 2.416

5.  Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies.

Authors:  Heather J Baer; Laura C Collins; James L Connolly; Graham A Colditz; Stuart J Schnitt; Rulla M Tamimi
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

6.  The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.

Authors:  Tal Distelman Menachem; Yael Laitman; Bella Kaufman; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-06-11       Impact factor: 2.375

Review 7.  The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease.

Authors:  César Cobaleda; Juan Jesús Cruz; Rogelio González-Sarmiento; Isidro Sánchez-García; Jesús Pérez-Losada
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

8.  Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases.

Authors:  Alison Y Ting; Bruce F Kimler; Carol J Fabian; Brian K Petroff
Journal:  Cancer Prev Res (Phila)       Date:  2008-12

9.  Human chorionic gonadotropin (hCG) prevents the transformed phenotypes induced by 17 beta-estradiol in human breast epithelial cells.

Authors:  Hilal Kocdor; Mehmet A Kocdor; Jose Russo; Kara E Snider; Johana E Vanegas; Irma H Russo; Sandra V Fernandez
Journal:  Cell Biol Int       Date:  2009-07-30       Impact factor: 3.612

10.  Development of the human breast.

Authors:  Asma Javed; Aida Lteif
Journal:  Semin Plast Surg       Date:  2013-02       Impact factor: 2.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.